  | Today's Top Story |  |  | | - Review: Transgenic pig tissue transplant clinical trials coming soon
Human trials involving the transplant of pig tissues to treat diabetes, brain diseases and blindness could start within two years, according to researchers from the Thomas Starzl Transplantation Institute at the University of Pittsburgh. The researchers said "great strides" have been made in technology that could genetically engineer pig tissue for transplant. Robin Weiss, a professor of virology at University College, London, said patients who undergo such procedures should be closely monitored for retroviruses. The Independent (London) (10/21)        | Earn 3X rewards points when you fly with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
•For a limited time, 50K bonus points when you spend $10K your first 5 months
LEARN MORE AND APPLY |
  - Pentagon awards $13.6M for lung cancer detection research
The Department of Defense Lung Cancer Research Program has awarded Boston University School of Medicine $13.6 million to conduct a two-phase study on the potential of molecular biomarkers to diagnose lung cancer. The initial phase will involve examining the CT scans of 500 smokers to identify who will require a lung biopsy or close monitoring, and the second phase will involve 1,000 individuals who are vulnerable to lung cancer to spot biomarkers that could flag high-risk patients. Mass High Tech (Boston) (10/19) - UC San Diego to develop high-volume bioinformatics tools
Scientists at the University of California, San Diego, and the California Institute for Telecommunications and Information Technology will develop tools and models to help researchers analyze large-scale genetic sequencing data, configure or program analyses, and more efficiently and intuitively execute work flows. The project is being funded by a $1.4 million grant from the National Science Foundation. GenomeWeb Daily News (10/19)  | Enterprise Resource Planning automates many aspects of an organization's operations, cascading across traditional boundaries of operations, finance, manufacturing and more. As such, changes in the ERP market can cause a ripple effect in your business. Get ahead of the changing tide and trends by downloading this free whitepaper. |
 - Companies have cystic fibrosis drugs in the pipeline
More than 20 years after scientists identified the gene that causes cystic fibrosis, several companies have drugs in the pipeline, including Vertex Pharmaceuticals, which recently filed for FDA approval of a treatment that targets a specific mutation. Other companies with drugs in the works include Pfizer and PTC Therapeutics. One Wall Street analyst predicted that such drugs could cost as much as $200,000 annually for each patient. The Wall Street Journal (tiered subscription model) (10/20) - Halozyme tech enables subcutaneous delivery of Roche's Herceptin
Under-the-skin delivery of Roche Holding's breast cancer drug Herceptin appears as safe and effective as the approved IV administration for treating an aggressive type of early-stage breast cancer, according to data from a Phase III study. The subcutaneous formulation uses drug-delivery technology based on the enzyme rHuPH20, from Halozyme Therapeutics. San Diego Union-Tribune (10/18)  | Organizations who handle payment card data are obligated to comply with the Payment Card Industry Data Security Standard (PCI DSS). This whitepaper discusses how the TransArmor® solution can enable scope reduction, minimizing costs and effort of PCI compliance. |
- Monsanto is getting into the produce-seed market
Monsanto is entering the produce-seed market and building a new seed line to rival its soybean business in the coming years. The company plans to design better vegetables to help farmers grow plants with improved taste and yields while using fewer resources. Los Angeles Times (10/20)  | FREE TRIAL – Thomson Reuters Cortellis™ Pipeline Intelligence
Discover new opportunities in drug development and licensing faster. Cortellis gives you an innovative way of finding and acting on drug pipelines, deals, patents, companies, breaking industry news, and conference coverage in one source, intuitively presented.
Click here to see if you qualify for a free trial! |
 | Industrial & Environmental | | | | | News from BIO | | | | - Greater breadth of companies. Greater depth of knowledge.
The 10th Annual BIO Investor Forum, Oct. 25 and 26 in San Francisco, is a national investor forum exploring investment trends and opportunities in life sciences. Hear presentations from over 110 late-stage private and emerging public companies you won't see at other investor conferences. Meet one-on-one with new and current investors, analysts, and partnering companies. Gain insights from expert physicians, analysts, and company scientific officers at candid therapeutic and business panels. For program registration and more information, visit the BIO Investor Forum website.
| SmartQuote | | | |  | Never refuse any advance of friendship, for if nine out of ten bring you nothing, one alone may repay you."
--Claudine Guérin de Tencin,
French socialite and author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, October 20, 2011
- Wednesday, October 19, 2011
- Tuesday, October 18, 2011
- Monday, October 17, 2011
- Friday, October 14, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment